Accepted for Publication:: March 9, 2011.
Published Online: May 9, 2011. doi:10.1001/archneurol.2011.99
Author Contributions:Study concept and design: Caplan, Arenillas, Cramer, Joutel, Lo, Meschia, Savitz, and Tournier-Lasserve. Acquisition of data: Arenillas. Analysis and interpretation of data: Caplan and Arenillas. Drafting of the manuscript: Caplan, Arenillas, Cramer, Joutel, Lo, Meschia, Savitz, and Tournier-Lasserve. Critical revision of the manuscript for important intellectual content: Caplan, Arenillas, and Joutel. Statistical analysis: Arenillas. Obtained funding: Joutel. Administrative, technical, and material support: Cramer and Joutel. Study supervision: Caplan, Arenillas, Joutel, Savitz, and Tournier-Lasserve.
Financial Disclosure: Dr Cramer has received grant funding from GlaxoSmithKline and Stem Cell Therapeutics and has been a consultant to GlaxoSmithKline, Stem Cell Therapeutics, Pfizer, Photothera, Allergan, and Asubio.
Additional Information: Dr Meschia provided material on genome-wide association studies. Dr Joutel provided the section on CADASIL. Dr Tournier-Lasserve provided materials on COL4A1 and CCM mutations. Dr Lo provided the section on therapeutic targets, animal models, and testing of biomarkers. Dr Arenillis provided the section on blood biomarkers. Dr Savitz wrote the section on cell-based therapies. Dr Cramer authored the section on recovery. Dr Caplan edited and collated the material and provided the section on collagen mutations and arterial dissections.